Biocryst Pharmaceuticals Inc
Research Biocryst Pharmaceuticals Inc (BCRX) on Bullrun: market cap USD 2.51B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBCRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 2.51B
- Financial periodQ2 2026
- RevenueUSD 218.25M
- Net incomeUSD 78.40M
- Free cash flowUSD 104.13M
- Gross margin98.2%
Valuation Snapshot
latest market cap is USD 2.51B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 874.84M | USD 263.86M | USD 344.90M | 97.8% | 1.21 | USD 89.74M | USD 0 | -USD 119.15M |
| FY2024 | USD 450.71M | -USD 88.88M | -USD 53.14M | 97.3% | -0.43 | USD 104.71M | USD 314.87M | -USD 475.93M |
| FY2023 | USD 331.41M | -USD 226.54M | -USD 97.31M | 98.6% | -1.18 | USD 110.64M | USD 303.23M | -USD 455.53M |
| FY2022 | USD 270.83M | -USD 247.12M | -USD 163.20M | 97.6% | -1.33 | USD 304.77M | USD 231.62M | -USD 294.60M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.51B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.66B | 6.5 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.57B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.23B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.14B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.55B | n/a | n/a | n/a |
About Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biocryst Pharmaceuticals Inc's market cap?
Biocryst Pharmaceuticals Inc's market capitalization is USD 2.51B.
What does Biocryst Pharmaceuticals Inc do?
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.